MusclePharm Competitors

Delisted . USA . 
Stock . MusclePharm
MusclePharm competes with Griffon, Acm Research, ServiceNow, RBC Bearings, and Uber Technologies; as well as few others. The company classifies itself under Food Products sector and is part of Consumer Staples industry. Analyzing MusclePharm competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of MusclePharm to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of MusclePharm competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.000.000.00
Details
Intrinsic
Valuation
LowRealHigh
0.000.000.00
Details
Naive
Forecast
LowNextHigh
0.00010.00010.0001
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
000
Details

MusclePharm Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between MusclePharm and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of MusclePharm and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of MusclePharm does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
RBC
+ 0.9
GFF
ALNT
+ 0.89
NOW
ALNT
+ 0.87
GFF
UBER
+ 0.83
ACMR
ALNT
+ 0.79
RBC
NOW
+ 0.74
GFF
  
High negative correlations   
UBER
- 0.81
NOW
ALNT
- 0.69
UBER
NOW
- 0.69
ACMR
ALNT
- 0.61
PSFE
ALNT
- 0.6
ACMR
PSFE
- 0.55
NOW

Risk-Adjusted Indicators

There is a big difference between MusclePharm Pink Sheet performing well and MusclePharm Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze MusclePharm's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

MusclePharm Competitive Analysis

The better you understand MusclePharm competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, MusclePharm's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across MusclePharm's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
GFF ACMR NOW RBC UBER UNMK PSFE ALNT
 0.04 
 78.13 
Griffon
 1.44 
 18.42 
Acm
 0.80 
 1,134 
ServiceNow
 2.42 
 315.33 
RBC
 0.71 
 68.30 
Uber
 0.00 
 0.08 
Tritent
 2.89 
 18.15 
Paysafe
 2.55 
 26.54 
Allient
Market Volatility
(90 Days Market Risk)
Very steady
Somewhat reliable
Very steady
Very steady
Very steady
Very steady
Not too volatile
Very steady
Market Performance
(90 Days Performance)
OK
Very Weak
Good
OK
Very Weak
Very Weak
Very Weak
Solid
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Low
Low
Low
Above Average
Average
Very Small
Current Valuation
(Equity Enterprise Value)
Under Valued
Over Valued
Under Valued
Under Valued
Over Valued
Over Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Strong Buy
Strong Buy
Strong Buy
Buy
Strong Buy
Not Available
Hold
Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Buy
Strong Sell
Strong Buy
Strong Buy
Strong Sell
Strong Sell
Hold
Buy
Current Ratio
2.26 X
3.56 X
1.24 X
2.77 X
1.04 X
N/A
1.06 X
N/A
Net Asset
2.37 B
1.49 B
17.39 B
4.68 B
38.7 B
1.71 M
5.23 B
597.54 M
Profit Margin
0.08 %
0.12 %
0.13 %
0.14 %
0.10 %
N/A
(0.01) %
0.03 %
EBITDA
461.44 M
126.99 M
1.29 B
459.8 M
1.93 B
N/A
435.88 M
67.15 M
Operating Margin
0.20 %
0.22 %
0.15 %
0.22 %
0.09 %
N/A
0.08 %
0.06 %
Current Valuation
5.33 B
972.6 M
229.09 B
11.22 B
147.42 B
(600.26 K)
3.37 B
655.01 M
Price To Book
16.61 X
1.32 X
24.99 X
3.52 X
9.73 X
N/A
1.30 X
1.60 X
Retained Earnings
461.44 M
156.83 M
2.07 B
1.22 B
(30.59 B)
(2.9 M)
(2.26 B)
165.81 M
Current Asset
382.34 M
162.49 M
1.09 B
1.64 B
N/A
9 K
N/A
N/A
Five Year Return
1.48 %
N/A
N/A
1.34 %
N/A
N/A
N/A
N/A
Beta
1.27
1.54
0.99
1.52
1.34
-13.72
1.92
1.51
Number Of Employees
N/A
1.59 K
22.67 K
5.3 K
30.8 K
5
3.2 K
2.29 K
Shares Outstanding
47.82 M
57.61 M
206.32 M
31.41 M
2.11 B
3.39 M
60.77 M
16.85 M
Cash Flow From Operations
380.04 M
(75.32 M)
3.4 B
274.7 M
3.58 B
(214.62 K)
234.02 M
45.04 M
Annual Yield
0.01 %
N/A
N/A
N/A
N/A
N/A
N/A
0 %
Total Debt
1.71 B
99.1 M
2.28 B
1.29 B
11.83 B
N/A
2.53 B
243.49 M
Return On Equity
0.78
0.12
0.16
0.0811
0.34
N/A
-0.0268
0.0563
Z Score
N/A
N/A
N/A
N/A
N/A
-1.4
N/A
N/A
Return On Asset
0.12
0.0509
0.047
0.0475
0.0403
N/A
0.0188
0.0345
Number Of Shares Shorted
2.46 M
4.46 M
3.61 M
566.64 K
52.34 M
N/A
1.34 M
179.96 K
Book Value Per Share
4.83 X
14.20 X
45.03 X
98.76 X
7.02 X
0.18 X
14.45 X
16.20 X
Current Liabilities
189.15 M
89.65 M
731.64 M
612.8 M
N/A
1.38 M
N/A
N/A
Total Asset
2.37 B
1.49 B
17.39 B
4.68 B
38.7 B
1.71 M
5.23 B
597.54 M
Debt To Equity
1.97 %
0.04 %
0.47 %
0.67 %
1.52 %
N/A
2.96 %
N/A
Short Ratio
6.42 X
2.63 X
3.07 X
2.85 X
1.75 X
N/A
4.21 X
1.59 X
Target Price
101.0
29.0
1118.32
340.6
89.11
N/A
21.17
29.33
Last Dividend Paid
0.6
N/A
N/A
N/A
N/A
N/A
N/A
0.12
Shares Owned By Institutions
77.80 %
61.38 %
91.93 %
98.30 %
84.21 %
N/A
53.18 %
65.66 %
Market Capitalization
3.74 B
1.17 B
232.14 B
9.9 B
143.82 B
169.39 K
1.14 B
447.08 M
Price To Earning
19.62 X
9.52 X
415.52 X
116.63 X
N/A
N/A
N/A
N/A
Price To Earnings To Growth
2.36 X
0.21 X
3.04 X
1.45 X
0.72 X
N/A
N/A
N/A
Price To Sales
1.42 X
1.61 X
22.18 X
6.22 X
3.43 X
N/A
0.67 X
0.81 X
Net Income
209.9 M
77.35 M
1.73 B
209.9 M
1.89 B
(214.62 K)
(20.25 M)
24.1 M
Earnings Per Share
4.23 X
1.33 X
6.41 X
6.87 X
2.03 X
N/A
(0.39) X
0.87 X
Shares Owned By Insiders
18.29 %
15.05 %
0.18 %
1.70 %
0.18 %
N/A
24.08 %
15.88 %
Revenue
2.62 B
557.72 M
8.97 B
1.56 B
37.28 B
N/A
1.6 B
578.63 M
Working Capital
580.49 M
675.45 M
412 M
671.2 M
1.84 B
(1.37 M)
193.82 M
152.53 M
Cash And Equivalents
120.18 M
417.64 M
1.47 B
65.4 M
4.21 B
1.7 M
220.19 M
N/A
Cash Per Share
2.81 X
7.05 X
19.55 X
4.17 X
2.44 X
0.24 X
0.30 X
N/A
Gross Profit
1.06 B
359.82 M
8.29 B
694.4 M
13.72 B
N/A
993.43 M
171.69 M
Day Typical Price
78.33
18.39
1127.72
318.07
67.97
0.082
18.25
26.27
Accumulation Distribution
3129.8
13758.48
18402.15
4237.98
253640.0
N/A
9204.49
2515.21
Market Facilitation Index
0.0
0.0
0.0
1.0E-4
N/A
N/A
0.0
0.0
Daily Balance Of Power
0.0265
(0.71)
0.4643
(0.89)
0.4248
0.0
(0.76)
0.6735
Period Momentum Indicator
0.03
(0.27)
9.03
(7.83)
0.48
N/A
(0.54)
0.66
Rate Of Daily Change
1.0
0.99
1.01
0.98
1.01
1.0
0.97
1.03
Day Median Price
78.43
18.37
1124.47
319.45
67.81
0.082
18.3
26.14
Price Action Indicator
(0.28)
(0.09)
14.24
(8.03)
0.73
N/A
(0.42)
0.73
Relative Strength Index
42.43
46.18
48.24
34.06
52.97
N/A
40.56
60.97
Coefficient Of Variation
1163.17
13379.19
526.11
1230.69
(1,168)
N/A
(1,483)
525.6
Mean Deviation
1.73
2.49
1.34
1.04
1.57
N/A
2.13
2.08
Jensen Alpha
0.2093
0.0145
0.3103
0.1112
(0.22)
N/A
(0.31)
0.4775
Total Risk Alpha
0.1109
(0.16)
0.2484
0.053
(0.33)
N/A
(0.45)
0.401
Sortino Ratio
0.1018
(0)
0.1845
0.0817
N/A
N/A
N/A
0.1754
Downside Variance
4.01
16.07
2.47
1.27
N/A
N/A
N/A
7.78
Standard Deviation
2.93
3.95
1.78
1.72
2.42
N/A
3.89
2.82
Kurtosis
21.29
5.65
2.1
15.75
5.47
N/A
26.35
1.6
Potential Upside
2.88
5.6
2.58
2.22
2.67
N/A
5.19
4.75
Treynor Ratio
0.2814
0.1481
0.7113
0.2629
(2.31)
N/A
(0.29)
0.403
Maximum Drawdown
22.89
23.61
11.04
12.57
12.29
N/A
31.72
17.5
Variance
8.59
15.63
3.16
2.97
5.87
N/A
15.16
7.98
Market Risk Adjusted Performance
0.2914
0.1581
0.7213
0.2729
(2.30)
N/A
(0.28)
0.413
Risk Adjusted Performance
0.0802
0.0142
0.1669
0.0742
(0.07)
N/A
(0.05)
0.1688
Skewness
3.47
0.0538
0.3692
3.05
(1.78)
N/A
(4.06)
(0.13)
Semi Deviation
1.79
3.94
1.28
0.9475
N/A
N/A
N/A
2.37
Information Ratio
0.0696
(0)
0.1631
0.0534
(0.11)
N/A
(0.08)
0.1732
Value At Risk
(3.57)
(6.14)
(2.38)
(1.80)
(5.35)
N/A
(3.45)
(4.50)
Expected Short fall
(1.97)
(2.51)
(1.53)
(1.20)
N/A
N/A
N/A
(2.31)
Downside Deviation
2.0
4.01
1.57
1.13
N/A
N/A
N/A
2.79
Semi Variance
3.2
15.53
1.63
0.8977
N/A
N/A
N/A
5.6

MusclePharm Competition Performance Charts

Five steps to successful analysis of MusclePharm Competition

MusclePharm's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by MusclePharm in relation to its competition. MusclePharm's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of MusclePharm in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact MusclePharm's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to MusclePharm, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your MusclePharm position

In addition to having MusclePharm in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Rentals Thematic Idea Now

Rentals
Rentals Theme
Companies providing rental and leasing services to public and business. The Rentals theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Rentals Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Other Consideration for investing in MusclePharm Pink Sheet

If you are still planning to invest in MusclePharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MusclePharm's history and understand the potential risks before investing.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY